Stories

Cultural reportage
on the GLP-1 era.

Personal essays and analysis on Ozempic, weight-loss drugs, and the culture they created. Published intermittently. Always cultural, never prescriptive. Subscribe to the monthly letter to get the next one in your inbox.

Not medical advice, a cultural conversation. Ozemback is not affiliated with any pharmaceutical company or healthcare provider.

All stories.

Analysis · Regulation

When will survodutide be approved? The FDA timeline and the phase 3 data

The obesity trials are finished and the filing is set for 2027. The liver indication runs years behind, and tolerability is the open question.

9 min read · November 15, 2026
Read more →
Analysis · Regulation

When will retatrutide be approved? The FDA timeline and the court case

The trials are finished and the filing is set for early 2027. The open question is whether the FDA reviews it as a biologic or as a drug.

9 min read · November 14, 2026
Read more →
Analysis · Regulation

When will CagriSema be approved? The FDA timeline and the trial data

Filed on 18 December 2025, a decision expected in the last quarter of 2026, a launch planned for early 2027, and one head-to-head trial that went to tirzepatide.

8 min read · November 12, 2026
Read more →
Analysis · Market / Access

How does LillyDirect work? Prices, pharmacies and the 45-day rule

One address for the prescription, four outside pharmacies that dispense, a cash price Lilly sets, and a refill clock that moves the higher strengths from $449 to $699.

9 min read · November 11, 2026
Read more →
Analysis · Regulation / Peptides

Are peptides legal now? What the HHS peptide policy actually allows

A draft promise not to enforce, for six peptides, specific salts and routes, and licensed pharmacies only. The law and the 503A list have not moved.

8 min read · November 4, 2026
Read more →
Analysis · Coverage / Medicare

Does Medicare cover Wegovy and Zepbound for weight loss?

Yes, since July 2026, through a $50 demonstration outside Part D that ends on 31 December 2027. Who qualifies, why vials are out, and what comes after.

8 min read · November 1, 2026
Read more →
Analysis · Legal / enforcement

Who regulates GLP-1 and peptide advertising: the FDA or the FTC?

The "FTC crackdown" is mostly an FDA story. A 1971 agreement, 55 FDA letters in 2026, the FTC’s NextMed and Hims cases, and the gap where research peptides sell.

8 min read · October 31, 2026
Read more →
Analysis · Market / supply chain

Where do research peptides come from? The supply chain behind the vial.

The label says where a vial was packed. FDA import alerts, a customs seizure of 5,000 parcels and 2026 import data say where the powder was made, and who inspected the plant.

8 min read · October 29, 2026
Read more →
Analysis · Legal / market

Can you get peptides through telehealth? What the law allows.

The video call is rarely the legal problem. The molecule and the pharmacy are, and the DEA deadline of 31 December matters for testosterone, not BPC-157.

8 min read · October 28, 2026
Read more →
Essay · New

The third way. A cultural letter on the year the body conversation changed.

For a century the equation had two terms: diet and exercise. Then a generation woke up and the sentence had a third. An essay on what that third sentence does to a culture.

9 min read
Read more →

One thoughtful letter, once a month.

The cultural essays, the reading recommendations, the conversation behind the next piece. First Sunday of every month.

Subscribe to the letter
Ozemback is independent journalism. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Read the disclaimer